Clinical DevelopmentOnKure's lead candidate is OKI-219, a mutant-selective PI3Kα inhibitor, which is in Phase 1 for the treatment of solid tumors, with initial results expected at the upcoming SABCS annual meeting.
Financial OutlookAnalysts forecast peak non-risk-adjusted global OKI-219 revenues of $1.05B in H1047R+, HR+, HER2- breast cancer and $440M in late-line H1047R+ solid tumors.
Financial PositionOnKure ended 3Q24 with $76.7M in cash, which should be sufficient to provide an operational runway into 2026.